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Abstract
T-cell replete hematopoietic stem cell transplantation (HSCT) from a haploidentical donor followed by high doses of
cyclophosphamide has been demonstrated to provide the best chances of a cure for many children in need of an allograft but
who lack both a sibling and an unrelated donor. In this study we retrospectively compared the outcome of pediatric patients
undergoing T-replete haploidentical HSCT (Haplo) for acute leukemia with those undergoing transplantation from unrelated
HLA-matched donor (MUD) and HLA mismatched unrelated donor (MMUD) from 2012 to 2017 at our Center. Both
univariable and multivariable analyses showed similar 5-year overall survival rates for MUD, MMUD, and Haplo patients:
71% (95% CI 56–86), 72% (95% CI 55–90), and 75% (95% CI 54–94), respectively (p= 0.97). Haplo patients showed
reduced event-free survival rates compared to MUD and MMUD patients: 30% (95% CI 12–49) versus 70% (95% CI
55–84) versus 53% (95% CI 35–73), respectively (p= 0.007), but these data were not confirmed by a multivariable analysis.
Non-relapse mortality (NRM) and relapse incidence (RI) were similar for the three groups. Therefore, our data confirm that
Haplo is a suitable clinical option for pediatric patients needing HSCT when lacking both an MUD and an MMUD donor.
Introduction
For many pediatric patients affected by acute leukemia,
allogeneic hematopoietic stem cell transplantation
(alloHSCT) can offer the best chances for long-lasting
disease control [1], however only 25% of patients needing
alloHSCT have an HLA-identical sibling and an unrelated
donor can be identified in only 60% of the remaining cases
[2]. Moreover, the likelihood of finding an unrelated donor
strictly depends on the patient’s ethnicity with higher
probabilities for Caucasians compared to other ethnic
groups [3]. For these patients, currently available options
are transplantation from a cord blood unit or from a relative
donor sharing only one HLA-haplotype with the recipient
(Haplo HSCT) [2]. However, since 2009 the number of cord
blood alloHSCTs has been in continuous decline and most
of the transplant centers have adopted strategies based
on Haplo HSCT [4–6]. Today, there are currently three
strategies available when performing Haplo HSCT which
are (1) based on the infusion of a high dose of Cyclopho-
sphamide into the recipient, following stem cell infusion, to
eliminate any alloreactive T-cells (CTX-Haplo HSCT) [7].
(2) the administration of a very intensive GvHD prophy-
laxis combined with the use of G-CSF primed bone marrow
as stem cells source [8], and (3) the depletion of TCR
alpha–beta and CD19+ cells from the graft [9]. In pediatric
patients affected by acute leukemia promising clinical
results have been reported, mainly with TCR alpha–beta
CD19 depleted Haplo HSCT [10] and with CTX-Haplo
HSCT [11].
Considering the increasing number of Haplo HSCT
patients, it is crucial to understand if transplantation outcomes
with these approaches are similar to those of more con-
solidated approaches such as matched unrelated donor (MUD)
HSCT and mismatched unrelated donor (MMUD) HSCT.
CTX-HaploSCT has recently been compared to MUD
and MMUD HSCT in some large retrospective trials with
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adult patients who were mainly affected by acute myelo-
genous leukemia with some authors concluding that CTX-
Haplo HSCT results are similar to those of MMUD but
inferior to those of MUD [12, 13], while others highlighting
a comparable outcome with all three kinds of donor [14].
For acute lymphoblastic leukemia in adult patients, the
results of CTX-Haplo HSCT have been reported to be very
similar to those obtained by MUD and MMUD HSCT
[15, 16]. Pediatric specific data at the time of this study are
lacking so since it has been demonstrated that a patient’s
age plays a significant role in determining these CTX-Haplo
HSCT results [17], we compared the results of CTX Haplo
HSCT to MUD and MMUD HSCT in the treatment of




Our study included all patients undergone first alloHSCT
for hematological malignancies from (1) an HLA-MUD,
(2) an HLA-MMUD, (3) a related HLA-haploidentical
donor (Haplo) at our Center between January 1, 2012 and
December 31, 2017. All data were retrieved retrospectively
from clinical records according to the policy approved by
our Institutional Committee on Medical Ethics and after
obtaining informed consent from parents or legal guar-
dians. Both the selection of the donor and HLA typing were
performed according to the Italian Bone Marrow Donor
Registry Standard of Practice that includes high-resolution
molecular typing of loci HLA-A, -B, -C, DRB1, and
DQB1. MUD was considered a ten out of ten antigens
HLA-MUD and MMUD a nine out of ten antigens HLA-
MUD. Haploidentical donors were family members with
one identical HLA-haplotype and the other mismatched
haplotype, as previously defined [18]. The decision to
perform Haplo HSCT was based on the absence of both ten
out of ten antigens and nine out of ten HLA-MUD. In the
case of Haplo HSCT, following our previous observations
[11], our first choice of donor was the patient’s mother
independently of the patient’s sex. Where the mother pre-
sented clinical contraindications to stem cell collection or if
the patient presented specific anti-HLA antibodies, we
chose the patient’s father or another close relative. In cases
where patients had positive donor-specific anti-HLA anti-
bodies and no other related donor was available, our
patients were treated according to previously reported
indications [19]. The Haplo HSCT was based on the non-
myeloablative (NMA) conditioning regimen reported by
Luznik et al. [7] including Cyclophosphamide (29 mg/kg),
Fludarabine (150 mg/mq), and total body irradiation (TBI)
(2 Gy in single fraction). The GvHD prophylaxis was based
on the administration of a high dosage of Cyclopho-
sphamide (total dose 100 mg/kg) on days +3 and +4 after
HSCT, Tacrolimus and Mofetil Mycophenolate. The MUD
and MMUD HSCT were performed using a full myeloa-
blative conditioning (MAC) regimen including the asso-
ciation of TBI (1200 cGy in six fractions for a total of
3 days of treatment), Thiotepa (10 mg/kg) and Cyclopho-
sphamide (120 mg/kg) or Busulfan (16 mg/kg), Cyclopho-
sphamide (120 mg/kg), and Melphalan (140 mg/mq). The
GvHD prophylaxis in these latter cases included rabbit
anti-human thymocytes globulins (ATG-Grafalon, Neovii
or Thymoglobuline, Sanofi), Cyclosporine and short course
of Methotrexate.
We included patients receiving either bone marrow or
peripheral blood hematopoietic stem cells as stem cell
source, while cord blood HSCTs were excluded. Our
patients underwent clinical and hematological assessments
both before and after transplantation following our Center
Standard Operating Policies.
Definitions and endpoints
The main aim of this study was to compare the overall
survival rates (OS) of patients who had undergone Haplo
HSCT to the OS rates of patients who had undergone MUD
and MMUD HSCT at our Center for acute lymphoblastic
leukemia and acute myelogenous leukemia. The secondary
endpoints were differences in terms of event-free survival
(EFS), non-relapse mortality (NRM), relapse incidence
(RI), incidence of both acute (aGvHD) and chronic GvHD
(cGvHD), achievement of full donor cell engraftment, and
immune recovery in the three groups of patients. For OS,
EFS, NRM, and RI an initial set of univariable analyses
were performed considering the following variables: HSCT
type, sex, age, disease type, disease risk index (DRI), and
occurrence of both aGvHD and cGvHD. Following this, the
same variables were combined in multivariable analysis
models. DRI was evaluated as previously described [20]
and aGvHD and cGvHD were diagnosed and graded
according to the published criteria [21, 22].
OS is defined as the probability of survival irrespective
of the disease state at any point in time. If the patient is still
alive at the end of the study data are censored on the date of
the last follow-up.
EFS is defined as the probability of survival with com-
plete disease remission and with sustained donor cell
engraftment. If the patient is still alive at the end of the
study, in complete disease remission and without any signs
of both primary and secondary graft rejection, data are
censored on the date of the last follow-up.
NRM is defined as the probability of dying without the
occurrence of a previous relapse. If the patient experienced
F. Saglio et al.
relapse or is still alive by the end of the study, data are
censored on the relapse date or on the date of the last
follow-up.
RI is defined as the probability of having had a relapse.
If the patient died without experiencing relapse or is
still alive by the end of the study, data are censored on
the date of death or on the date of the last follow-up,
respectively.
In the Haplo CTX HSCT group, we also retrospectively
investigated the impact of NK alloreactivity on RI by ana-
lyzing for killer immunoglobulin receptors (KIR) in the
donor and recipient, as previously described [23].
Donor chimerism was determined at day +45 ± 7 after
alloHSCT, and then when clinically indicated, on whole
bone marrow mononuclear cells by quantitative PCR of
informative short tandem repeats in the donor and recipient,
according to a method previously described [24].
Sustained donor cell engraftment was defined as the
presence of more than 1000 neutrophils/mmc and more
than 50,000 platelets/mmc for three consecutive days
without transfusion support and with a chimerism show-
ing more than 97% of the donor cells in the bone marrow
after HSCT.
Graft rejection was defined as a lack of initial engraft-
ment of donor cell graft (chimerism showing more than
50% of the recipient’s cells) or loss of donor cell engraft-
ment, independently from the peripheral cell blood count. In
the case of graft rejection, for NRM and RI analyses, data
were censored on the date of bone marrow assessment that
showed a chimerism with more than 50% of the recipient’s
cells. Immune recovery was investigated by multi-color
flow-cytometry on peripheral blood at different times
after HSCT and included the absolute enumeration of total
T-cells (CD3+), Helper T-cells (CD3+CD4+), Cytotoxic T-
cells (CD3+CD8+), NK-cells (CD16+CD56+), and B-cells
(CD19+CD20+).
Statistical analysis
To identify baseline differences among the three groups of
patients (MUD, MMUD, and Haplo), a two-tailed Fisher
test was performed.
OS and EFS were calculated according to the
Kaplan–Meier method with the significance between the
observed differences being established by log-rank testing.
Multivariable analyses on OS and EFS were performed
using Cox’s method. The NRM and RI were calculated as a
cumulative incidence (CI) to adjust the analysis for com-
peting risks: relapse and transplant-related death were
considered competing risks, respectively. aGvHD and
cGvHD were calculated as CI too. In these cases, disease
recurrence and death by any cause were considered com-
peting risks. The differences in terms of CI were compared
using Grey’s test. The NRM and RI multivariable analyses
were performed using logistic regression. In the Haplo
group, we also analyzed the impact on RI of NK allor-
eactivity in donor–recipient pairs according to KIR match-
ing. To evaluate for differences in the achievement of
the donor’s cell engraftment, a two-tailed Fisher test
was performed. Data concerning specific lymphocytes’ sub-
populations are reported as average ±standard deviation.
A p value < 0.05 was considered statistically significant in
all the analyses. All the statistical analyses were performed
using NCSS (Hintze, 2001; NCSS PASS, Number Crun-




The study included 90 patients (49 males and 41 females)
with a median age of 9 years (range 1–25) at the time of
alloHSCT: 41 (45%) patients had received MUD HSCT, 26
(29%) MMUD, and 23 (26%) Haplo. The patients’ char-
acteristics are summarized in Table 1. No statistically sig-
nificant baseline differences were observed in the three
groups of patients (Table 1). Analyses used October 31,
2019 as reference date, the median follow-up time of
patients enrolled in the study and who are still alive at the
end of the study is 4 years (range: 1.4–7). In the Haplo
group, two patients had positive donor-specific anti-HLA
Table 1 Patients’ characteristics.
MUD n= 41 MMUD n= 26 Haplo n= 23 p
Sex
Male 23 (56%) 13 (50%) 13 (58%) 0.82
Female 18 (44%) 13 (50%) 10 (42%)
Age
0–5 years 15 (36%) 6 (23%) 4 (21%) 0.54
6–10 years 12 (30%) 7 (27%) 11 (46%)
11–15 years 9 (22%) 7 (27%) 5 (21%)
>15 years 5 (12%) 6 (23%) 3 (12%)
Disease
ALL 24 (59%) 20 (77%) 7 (29%) 0.75
AML 17 (41%) 6 (23%) 16 (71%)
Disease risk index
Low 10 (24%) 4 (15%) 3 (12%) 0.37
Intermediate 25 (61%) 21 (81%) 18 (75%)
High 6 (15%) 1 (4%) 2 (13%)
MUD matched unrelated donor, MMUD mismatched unrelated donor,
Haplo haploidentical-related donor, ALL acute lymphoblastic leukemia,
AML acute myelogenous leukemia.
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antibodies and they received specific treatment before
starting the conditioning regimen.
Overall survival
The 5-year OS rate for the entire study population was 72%
(95% CI 62–82). Patients who had undergone HSCT from
MUD, MMUD, and Haplo showed a similar OS in uni-
variable analysis (Table 2 and Fig. 1): 71% (95% CI
56–86), 72% (95% CI 55–90), and 75% (95% CI 54–94),
respectively (p= 0.97). Among other variables investigated
in univariable analysis (age, sex, disease type, DRI,
aGvHD, and cGvHD), age and DRI showed a statistically
significant correlation with OS rates (Table 2). In a multi-
variable analysis, OS was confirmed to be similar across the
three study sub-groups and only age maintained a statisti-
cally significant correlation with OS. Patients older than 15
years showed a significant increased risk of mortality
compared to younger children (HR 6.83 95% CI 1.6–30
p= 0.007) (Table 3), while for MUD and MMUD patients
the main causes of death were infections and end-stage
Table 2 Overall survival (OS)
and event-free survival (EFS):
univariable analysis.
Overall survival Event-free survival
Variable n Events OS 95% CI p Events EFS 95% CI p
Sex
Female 41 9 76% 63–90 0.42 16 60% 44–75 0.4
Male 49 14 69% 54–82 24 51% 37–65
Age
0–5 years 25 4 78% 61–95 0.0014 7 71% 53–89 0.01
6–10 years 30 5 81% 67–96 14 53% 35–71
11–15 years 21 5 76% 57–94 8 62% 41–83
>15 years 14 9 36% 10–60 11 21% 0–42
Disease
ALL 61 16 70% 58–82 0.94 28 53% 40–65 0.69
AML 29 7 73% 57–89 12 59% 41–76
Disease risk index
Low 17 1 94% 82–100 0.01 5 70% 48–92 0.17
Intermediate 64 17 70% 57–83 29 53% 41–66
High 9 5 40% 12–77 6 33% 2–64
Donor type
MUD 41 11 71% 56–86 0.97 12 70% 55–84 0.007
MMUD 26 7 72% 55–90 12 54% 35–73
Haplo 23 5 75% 54–94 16 30% 12–49
Grade II–IV aGVHDa
Present 17 4 76% 56–97 0.79 5 70% 48–92 0.16
Absent 72 18 72% 61–84 34 52% 40–64
cGvHDb
Present 10 4 76% 65–87 0.89 4 60% 30–90 0.68
Absent 74 30 59% 47–70 30 59% 47–70
ALL acute lymphoblastic leukemia, AML acute myelogenous leukemia, MUD matched unrelated donor,
MMUD mismatched unrelated donor, Haplo haploidentical donor.
a89 evaluable patients.
b84 evaluable patients.
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Fig. 1 Overall survival of patients included in the study. MUD
matched unrelated donor, MMUD mis-matched unrelated donor,
Haplo haploidentical donor.
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organ toxicities (n= 13, 72%), for Haplo patients the main
cause of fatality was the recurrence of the original disease
(n= 3, 60%).
Event-free survival
The 5-year EFS of the entire study population was 55%
(95% CI 44–65). In univariable analysis patients who had
undergone Haplo showed reduced EFS compared to MUD
and MMUD patients: 30% (95% CI 12–49) versus 70%
(95% CI 55–84) versus 53% (95% CI 35–73), respectively
(p= 0.007). Among other variables investigated in uni-
variable analysis (age, sex, disease type, DRI, aGvHD, and
cGvHD), patient’s age also showed a statistically significant
correlation with EFS (Table 2). In the multivariable analysis
we did not observe a correlation between HSCT type and
EFS, while we highlighted that patients older than 15 years
had a significant increased risk of disease recurrence, death
in remission and autologous reconstitution compared to
younger children (HR 6.12 95% CI 1.9–19.7 p= 0.002)
(Table 3).
Non-relapse mortality
The 5-year NRM of the entire study population was 12%
(95% CI 6–21). Patients who had undergone Haplo CTX
HSCT showed no statistically significant different NRM
compared to MUD and MMUD patients: 8% (95% CI
2–31) versus 15% (95% CI 7–31) versus 14% (95% CI
4–45), respectively (p= 0.72). Among other variables, only
age showed a statistically significant correlation with NRM
(Table 4) both in univariable and in multivariable analyses:
patients aged between 5 and 10 years showed a reduced risk
of NRM (HR 2.18 × 10e−8 95% CI 6.25 × 10e−8− 7.59 ×
10e−7 p < 0.001) compared to other age groups.
Considering the incidence of complications that con-
tributed to NRM, among the ten patients who died in
disease remission in the MUD and MMUD group, we
observed four cases of bacterial infection, two cases of
viral infections, two cases of fungal infections, one case of
secondary hemophagocytic lympho-histiocytosis, and one
case of refractory heart failure. In the Haplo group, the
only patient dying from NRM had central nervous system
bleeding.
Relapse incidence
The RI of the entire study population was 16% (95% CI
10–26). Patients who underwent Haplo showed similar RI
compared to MUD and MMUD patients: 33% (95% CI
19–58) versus 15% (95% CI 7–30) versus 26% (95% CI
14–50), respectively (p= 0.25). In univariable analysis, age
showed a statistically significant correlation with RI
(Table 5) and these data were also confirmed in multi-
variable analysis: patients over 15 years showed increased
RI risk (HR 5.1 95% CI 1.2–22.3 p= 0.027) compared to
Table 3 Overall survival and
event-free survival:
multivariable analysis.
Variable Overall survival Event-free survival
Hazard ratio 95% CI p Hazard ratio 95% CI p
Sexa Male 1.96 0.4–1.75 0.21 1.37 0.6–2.8 0.39
Ageb 6–10 years 0.9 0.2–4.1 0.89 1.71 0.59–5 0.32
11–15 years 1.5 0.2–7.8 0.62 1.17 0.35–3.95 0.79
>15 years 6.83 1.6–30 0.007 6.12 1.9–19.7 0.002
Diseasec AML 0.31 0.03–2.5 0.16 1.22 0.13–11.14 0.85
Disease risk indexd low 0.49 0.04–6.64 0.59 0.94 0.09–10.08 0.96
high 1.7 0.16–18.3 0.2 0.91 0.09–9.38 0.94
Donor typee MUD 0.9 0.3–2.8 0.86 0.45 0.18–1.13 0.08
Haplo 0.9 0.23–3.5 0.89 1.95 0.82–4.7 0.13
Grade II–IV aGvHDf present 0.8 0.25–2.6 0.71 0.55 0.19–1.65 0.29
cGvHDg present 1.2 0.32–4.8 0.75 0.79 0.23–2.73 0.71
ALL acute lymphoblastic leukemia, AML acute myelogenous leukemia, MUD matched unrelated donor,
MMUD mismatched unrelated donor, Haplo haploidentical donor.
aCompared to female.





Statistically significant values are in bold.
Haploidentical HSCT with post transplantation cyclophosphamide versus unrelated donor HSCT in pediatric. . .
younger patients. In the Haplo sub-group, KIR-mismatch
patients did not have a different RI compared to KIR-
matched patients [25% (95% CI 4–100) versus 36% (95%
CI 20–66) (p= 0.59)].
GvHD incidence
Patients who had undergone Haplo HSCT showed a
reduced incidence of aGvHD compared to patients who
had undergone MUD and MMUD HSCT: 8% (95% CI
2–37) versus 14% (95% CI 6–30) versus 34% (95% CI
20–58), respectively (p= 0.004), while when considering
cGvHD, the patients who had undergone Haplo HSCT
showed a similar incidence of this complication compared
to MUD and MMUD patients: 5% (95% CI 1–35) versus
10% (95% CI 4–27) versus 16% (95% CI 6–39), respec-
tively (p= 0.51).
Donor cell engraftment
Full donor cell engraftment was achieved in 41 out of 41
(100%) of the evaluable patients had undergone MUD
HSCT, in 25 out of 25 (100%) of the evaluable patients who
had undergone MMUD HSCT, and in 17 out of the 23
(73%) evaluable patients who had undergone Haplo HSCT
(p < 0.0001).
Six patients from the Haplo group developed graft
rejection. They were affected by acute myelogenous leu-
kemia (n= 2) and acute lymphoblastic leukemia (n= 4).
Five of them underwent a second hematopoietic stem cell
transplantation using the same (n= 2) or an alternative
(n= 3) haploidentical stem cell donor. All patients at their
second HSCT had the same conditioning regimen and
the same GvHD prophylaxis as that used for their
first HSCT. As of October 31, 2019 they were all still alive:
Table 4 5 years non-relapse mortality (NRM): univariable analysis.
Variable n Events NRM 95% CI p
Sex
Female 41 2 5% 1–21 0.05
Male 49 8 19% 10–34
Age
0–5 years 25 2 12% 4–35 0.03
6–10 years 30 0 – –
11–15 years 21 5 23% 11–51
>15 years 14 3 26% 9–70
Disease
ALL 61 7 12% 6–26 0.76
AML 29 3 13% 5–33
Disease risk index
Low 17 1 6% 0.8–39 0.76
Intermediate 64 8 14% 7–27
High 9 1 11% 2–70
Donor type
MUD 41 6 15% 7–32 0.72
MMUD 26 3 14% 4–45
Haplo 23 1 8% 2–31
Grade II–IV aGVHDa
Present 17 1 6% 1–39 0.51
Absent 72 8 12% 6–23
cGvHDb
Present 10 2 20% 6–69 0.16
Absent 74 5 8% 0–19
ALL acute lymphoblastic leukemia, AML acute myelogenous leuke-
mia, MUD matched unrelated donor, MMUD mismatched unrelated
donor, Haplo haploidentical donor.
a89 evaluable patients.
b84 evaluable patients.
Statistically significant values are in bold.
Table 5 5 years relapse incidence (RI): univariable analysis.
Variable n Events RI 95% CI p
Sex
Female 41 9 22% 12–39 0.94
Male 49 12 24% 15–39
Age
0–5 years 25 3 11% 3–33 0.008
6–10 years 30 9 30% 17–51
11–15 years 21 2 9% 2–35
>15 years 14 7 50% 29–84
Disease
ALL 61 15 24% 16–38 0.61
AML 29 6 20% 9–40
Disease risk index
Low 17 2 12% 12–38 0.15
Intermediate 64 15 23% 14–40
High 9 4 44% 21–92
Donor type
MUD 41 6 15% 7–30 0.25
MMUD 26 7 26% 14–50
Haplo 23 8 33% 19–58
Grade II–IV aGvHDa
Present 17 3 18% 6–49 0.52
Absent 72 18 25% 17–37
cGvHDb
Present 10 2 20% 6–69 0.74
Absent 74 17 23% 15–35
ALL acute lymphoblastic leukemia, AML acute myelogenous leuke-
mia, MUD matched unrelated donor, MMUD mismatched unrelated
donor, Haplo haploidentical donor.
a89 evaluable patients.
b84 evaluable patients.
Statistically significant values are in bold.
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four of them are in complete disease remission with sus-
tained donor cell engraftment, while only one experienced
a second autologous reconstitution and he is currently alive
and disease free. The only patient who did not undergo
a second HSCT was lost to follow-up at +709 days
after HSCT.
Immune recovery
All the patients in the three groups displayed very similar
patterns in the recovery of the lymphocyte sub-populations
(Fig. 2).
Discussion
Our study showed that AlloHSCT can offer one of the best
chances of cure for the many children affected by acute
leukemia. Unfortunately, however, there is a significant
proportion of children for whom it is not possible to identify
either an HLA-identical sibling or an acceptable HLA-
MUD or MMUD. For these patients the use of an haploi-
dentical donor followed by the administration of a high dose
of cyclophosphamide is the most widely adopted strategy
both for its simplicity and reduced cost [25]. While for adult
patients undergoing Haplo CTX HSCT, several reports have
highlighted outcomes comparable to those of more con-
solidated approaches such as MUD and MMUD HSCT
unfortunately, pediatric specific data are still lacking.
However, this is the first study which was entirely focused
on a pediatric population which compared the outcomes of
patients undergoing Haplo CTX HSCT with those of
patients undergoing MUD and MMUD HSCT. Consistent
with the results from studies involving adult populations
[14–16], we have shown that patients who underwent
HSCT from MUD, MMUD, and Haplo have similar OS
rates [71% (95% CI 56–86), 72% (95% CI 55–90), and 75%
(95% CI 54–94), respectively (p= 0.97)], and we can also
confirm that this outcome measure is more likely related to
factors independent from HSCT type (i.e., patient’s age) as
previously described [26]. Previous experiences based on
NMA conditioning regimen in setting of pediatric Haplo
HSCT with post transplantation Cyclophosphamide repor-
ted lower OS and EFS rates compared to our results [27],
but we interpreted these differences as a consequence of an
higher RI related to the inclusion in the previous study of
high risk patients only, considering that our data confirmed
NRM under 15%.
The reduction of the survival rate of patients over 15
years old is in accordance with previous observations in the
literature that highlight that adolescents are usually affected
by more aggressive hematological malignancies and that
they also develop more serious transplant-related toxicities
compared to younger children [28], but the low number of
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Fig. 2 Mean ± standard deviation of (a) CD3+CD4+ cells, (b) CD3+CD8+ cells, (c) CD16+CD56+ cells, and (d) CD19+CD20+ cells at different
time points after transplantation.
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Considering that all the patients in the Haplo CTX HSCT
received a NMA conditioning regimen and that no statisti-
cally significant baseline differences were identified
according to the DRI of the three study sub-populations, the
similar OS rate among the three groups is quite remarkable
and our data may support the hypothesis that in the setting
of hematological malignancies, the immunological aspects
of HSCT are significant thus off-setting the intensity of the
conditioning regimen.
When analyzing for EFS, in univariable analysis, we
highlighted a statistically significant reduced probability of
survival in disease remission and with full donor cell
engraftment for Haplo HSCT patients compared to MUD
and MMUD patients [30% (95% CI 12–49) versus 70%
(95% CI 55–84) versus 53% (95% CI 35–73), respectively
(p= 0.007)] that was not confirmed by multivariable ana-
lysis. Since in our study population we did not observe any
significant correlation between HSCT type and RI and
NRM, neither in univariable nor in multivariable analyses,
we speculated that the reduced EFS of Haplo HSCT patients
related to an increased risk of autologous reconstitution; in
analyzing the donor cell engraftment we confirmed this
hypothesis, showing that it was possible to achieve full
donor cell engraftment in all the patients who had under-
gone MUD and MMUD HSCT, while six out of the 23
patients (73%) who had undergone Haplo CTX HSCT
experienced autologous reconstitution. Unfortunately, since
all the patients in the Haplo CTX group received a NMA
conditioning regimen, whereas all patients in the MUD and
MMUD group received a full MAC regimen, we were not
able to investigate the role of the intensity of the con-
ditioning regimen in determining the increased risk of
autologous reconstitution in our specific population, com-
pared also to previous reports about Haplo CTX HSCT,
even if this aspect has been described when an RIC regimen
was employed in this setting [29]. In order to reduce the risk
of autologous reconstitution, one possible strategy may be
the intensification of the conditioning regimen as it has been
described both for non-malignant disorders [30] and for
malignant disorders [31] by some single-institution trials.
Despite this, the majority of patients experiencing auto-
logous reconstitution in our study underwent a second
HSCT which was based on the same conditioning regimen
and the same GvHD prophylaxis in every case. Following
that, they showed similar OS rates compared to patients
undergoing MAC MUD and MMUD HSCT.
In consideration of transplant toxicity, our data confirm
that patients undergoing Haplo CTX HSCT have similar
NRM rates compared to patients undergoing MUD and
MMUD HSCT and, more specifically, when considering
GvHD, they also underline that the GvHD prophylaxis
based on the administration of high dose of Cyclopho-
sphamide is able to significantly reduce the incidence of
GvHD, especially in its acute form. As recently described
by Wachsmuth et al. [32], the mechanisms responsible for
the reduction in GvHD incidence observed with post
transplantation cyclophosphamide may rely on the periph-
eral elimination of alloreactive T-cells, on the intra-thymic
clonal deletion of alloreactive T-cell precursors, and on the
expansion of regulatory T-cells, but unfortunately, in our
study population we do not have any available data to
support any of these hypotheses.
One of the main concerns in adopting a strategy based on
a highly effective GvHD prophylaxis is the potentially
increased risk of relapse. However, in our study the RI was
not statistically different across the three groups of patients,
as has been described when other kinds of Haplo HSCT
have been compared to MUD and MMUD HSCT [33], and
data for immune recovery at different times after trans-
plantation suggest an equal graft versus leukemia effect.
When analyzing the graft versus leukemia effect in CTX
HSCT sub-group, we did not observe a protective KIR
alloreactivity role against disease recurrence which is con-
sistent with previous observations made in Haplo CTX
HSCT [11, 34]. Needless to say, the low number of patients
with KIR-mismatch included in our study and the reduced
size of the entire study population, unfortunately prevents
us from drawing conclusions in regard to this.
Our analysis of RI confirms that adolescents have an
increased risk of disease recurrence that we interpreted as a
consequence of the different disease biology in this age
group that has been previously described both for ALL [35]
and AML [36].
The main weakness of our study was the inclusion in the
Haplo CTX HSCT group of only patients having received
NMA conditioning regimen. This choice was mainly driven
by our Center policy based on a wider experience in using
this approach in comparison to MAC in the Haplo setting,
in a time-frame when data about MAC in CTX Haplo
HSCT [31] were not available yet. However, a more recent
and larger multicenter retrospective trial showed no differ-
ences in terms of RI between patients undergoing Haplo
CTX HSCT using either an RIC or an MAC [37], sug-
gesting that this aspect may not be crucial in this setting.
Some further significant limitations of our study are its
retrospective design and the inherent heterogeneity of some
of the patients’ characteristics, that we tried, at least par-
tially, to compensated by the use of a multivariable analysis.
In conclusion, our data confirm that CTX-Haplo HSCT is
a suitable clinical option that can offer pediatric patients
needing HSCT and lacking both an MUD and an MMUD
donor similar opportunities for long-lasting disease control.
The comparable risks of serious toxicity clearly have to be
taken into account and furthermore, there are some aspects
of this approach, such as the intensity of the conditioning
regimen, that still need to be worked on. However, the
F. Saglio et al.
results are promising, and it is hoped that in the future some
prospective clinical trials will be run in the pediatric
population to further improve the prognosis of children
affected by acute leukemia and in need of an allograft.
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